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1. Introduction
Multiple myeloma (MM) or plasma cell myeloma is a neoplastic proliferation of plasma cells
that primarily involves the bone marrow but may originate from extramedullary sites [1-4].
Although it is uncommon in veterinary medicine, it has been reported in several species, in‐
cluding cats, dogs and, horses [1,3,5-10]. The frequency of MM in cats is slightly <1% of all
malignant neoplasms. Canine MMs account for only 0.3% of all malignancies in dogs. MMs
account approximately 2% of all hematopoietic neoplasms in both dogs and cats [4]. Most of
the reports in the literature are limited to 1 to 16 case studies [4,11-16]. However, in a recent
report regarding the incidence of bone disorders diagnosed in dogs, MM was the second
most frequently diagnosed neoplastic condition in canine bone marrow [17].
Similarly, MM is an extremely rare disorder in horses. Ten cases, nine from the literature
and a new case, were described by Edwards et al. [1] and only six additional cases have
been described lastly [3,6-8,18]. Because of the uncommonly diagnosis of equine MM, the
prevalence of this neoplasm is unknown in the horse.
2. Data of the patients with multiple myeloma
MM is generally a disease of older animals, although some reports exist in young animals.
In dogs, the average age of diagnosis is between 8 and 12 year-old [9-10,15,19-25].There is a
report of MM in a younger dog, 4-year-old [26]. There is no apparent gender predisposition
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in dogs. Further, the largest retrospective study to date (60 dogs) included 30 males and 30
females [27].
The  mean age  of  diagnosis  in  cats  ranges  between 12.5  and 14  years,  and most  of  the
cats with MM are older than 7 year-old [28,29,4,30,31,32,33,9]. According to the literature,
the youngest  cat  with MM was 1.5  year-old [31].  A myeloma-related disorder has been
described  for  a  19-month-old  cat  [34].  Males  accounted  for  about  55-56%.  The  age  and
gender in dogs and cats with MM are similar to those described in human patients. In a
large retrospective study of 1027 people, the average age of diagnosis was 66 years and
59% were men [35].
MM is also a neoplasm of elderly horses, with mean age of 11 years at the moment of the
diagnosis [1]. Horses with this condition have ranged in age from three months to 25 years.
The youngest animals were a 1.6-year-old Quarter Horse mare [36] and a 3 month-old Quar‐
ter Horse colt [37]. Although it was suggested initially that it could be more common in
Quarter Horses [1], there are too few reports in equids for statistical interpretation of this
data. Both male (geldings and stallions) and female horses are represented equally.
3. Current knowledge of the etiology and predisposing factors of MM in
companion animals
Factors  associated  with  the  development  of  MM  in  companion  animals  have  not  been
identified.  In  human  patients,  exposure  to  high  doses  of  ionizing  radiation  has  been
linked to MM development according to  some studies  [38-40].  In  relation to  x-rays,  the
results  of  many  cohort  studies  in  human beings  have  been  inconsistent,  in  some cases
suggesting that frequent exposure has a negligible effect and in other that it is a signifi‐
cant risk [41-43]. In one report of equine MM, one horse was used regularly for teaching
radiology and Pusterla et al. [3] suggested that it might exists an association between ex‐
posure to x-rays and neoplastic transformation.
Genetic and hereditary factors may also play a role in MM development [44-45]. Recurrent
infections or antigen stimulation have been proposed as predisposing factors, although epi‐
demiological studies have not been confirmed this association [46]. Infections with several
virus diseases in human patients appear related to an elevated MM risk, although some data
do not support a potentially causal relationship between these infections and MM [46-50]. In
cats, a link between MM and virus such as feline leukemia virus (FeLV) and feline immuno‐
deficiency virus (FIV) has not been identified, but a diagnosis of the disease among sibling
suggests a familiar association [29]. The role of oncogenes, tumor-suppresor genes, cyto‐
kines, and their interaction with the bone marrow environment in the etiopathogenesis of
the MM are currently being investigated in animal models. Overexpression of cell cycle reg‐
ulators, such as cyslin D1 and disregulation of receptor tyrosine kinase have been implicated
in the pathogenesis of plasma cell tumors and MM [51]. Progression of B cell lymphoma to
MM and of solitary plasma cell tumors to MM in dogs and cats have been reported [52-53].
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4. Clinical signs
The infiltration of various organ systems by neoplastic cells, the production of cytokines by
the tumor or the bone marrow microenvironment, and the high circulating level of a single
type of immunoglobulin lead to a wide array of clinical manifestations. Therefore, the clini‐
cal signs of MM vary with the level of plasma cell proliferation, the location and spread of
the neoplastic plasma cells, and the nature and extent of the proteinuria [3,4,9-10,15,33,54].
The clinical signs are generally non-specific and include lethargy, renal failure, hemostatic
abnormalities, anorexia, diarrhea and vomiting in small animals and weight loss, anorexia,
fever, increased susceptibility to infections and limb edema in horses [1,3,8,11,36].
4.1. Increased susceptibility to infections
MM patients are usually immunocompromised and thus highly susceptible to infections
[55]. MM associated immunodeficiency is likely a multifaceted phenomenon secondary to
decreased concentration of polyclonal immunoglobulin [56], suppression of macrophage-re‐
lated factors influencing the normal B cell differentiation to plasma cells [57] in response to
antigenic stimulation [58], decreased T helper cell function, increased rate of γ-globulin ca‐
tabolism, neoplastic infiltration of bone marrow resulting in leukopenia [59], dysfunctional
and/or decreased numbers of neutrophils, and defective complement activation [3-4].
In cats with MM, the most common infectious processes include periodontitis, chronic re‐
current upper respiratory infections and terminal bacteriemia [4]. In horses with MM, the
most common system affected by infectious disease is the lung, with several cases of severe
pneumonia [1,3,37,60].
4.2. Bone pain and skeletal lesions
Bone pain is considered one of the most common presenting complaints in human patients
[61-62]. Skeletal abnormalities are commonly recognized in small animals, but uncommon in
horses with MM [1,3,63]. Horses frequently had bone lesions, therefore, bone pain might
manifest more as a gait abnormality and therefore, it could be misdiagnosed.
The percentage of cats with MM and radiographically-evident skeletal lesions was 58.3%
[2,4,13,63-66], similar to the 50-60% occurrence reported for dogs [27,64]. Skeletal lesions can
be either solitary (well-circumscribed with areas of osteolysis or punched-out lytic areas) or
multiple (generalized osteopenias) [4,27]. Rarely, pathologic fractures are seen. Skeletal le‐
sions are typically identified in bones involved in active hematopoiesis (e.g. ribs, vertebrae,
pelvis, and proximal and distal aspects of long bones). Other causes of focal osteolysis are
rare in companion animals, but include carcinomas [67], giant cell tumors of bone [68], be‐
nign aneurismal bone cysts [69-71] and bone lesions secondary to tumor invasion [70,72-73].
Generalized osteopenias have also been diagnosed radiographically [4]. Demineralization of
bone in humans is detected through measurement of bone mineral density, a technique not
used routinely in veterinary medicine. Generalized osteopenias is not specific for MM, and
may also be seen with nutritional, renal and metabolic disorders [74-77].




Bleeding is a prominent feature of MM in human beings [78-82]. Clinically, hemorrhages oc‐
cur in approximately one-third of dogs and one fourth of cats with MM [4,27,29]. In horses,
the most common clinical manifestation is epistaxis [1,3,6].
The pathogenesis of bleeding diathesis is likely multifactorial. The M-component may inter‐
fere with normal coagulation and lead to hemostatic defects by various mechanism that in‐
clude inhibition of platelet aggregation and release of platelet factor, adsorption of minor
clotting factors, induction of abnormal fibrin polymerization and functional decrease in cal‐
cium. In instances where myelophthisis is present due to profound bone marrow infiltra‐
tion, thrombocytopenia may develop and contribute to hemorrhagic events [24].
4.4. Hyperviscosity syndrome
The hyperviscosity syndrome (HVS) in characterized by clinico-pathologic  abnormalities
that occur secondarily to increased serum viscosity, which is associated with the M-com‐
ponent.  HVS is  most  commonly  associated  with  immunoglobulin-M macroglobulinemia
due to the high molecular weight of IgM [85]. However, it also can occur in presence of
IgA, and rarely with IgG [27].  HVS leads to bleeding diathesis,  neurological signs (such
as seizures,  depression, coma),  congestive heart failure,  renal failure and ophthalmic ab‐
normalities,  including tortuous and dilated retinal  vessels,  retinal  hemorrhages and reti‐
nal  detachment,  sludging  of  blood  within  small  vessels  and  impaired  delivery  of
nutrients and oxygen to tissues [84].
Approximately 20% of dogs with MM develop this syndrome and it has been reported in
cats [4,13,19,23,54,85]. There is a report that measured serum viscosity in a horse with MM
[86]. The horse had a serum concentration of globulin of 9.6 g/dl (reference range 3.5-4.5
g/dl) and a relative serum viscosity of 7 (reference range 1.4-1.7). In horses, edema is a com‐
mon clinical signs in MM [1,3]. The genesis of limb edema is unknown, although blood hy‐
perviscosity may be contributory. Increased vascular permeability has been proposed as a
cause of edema accompanying osteosclerosis myeloma in human beings [87].
4.5. Renal disease
Renal disease occurs in approximately 22-50% of dogs and about 30% of cats with MM
[4,27]. The pathogenesis of renal disease is commonly multifactorial and several mecha‐
nisms have been implicated in human patients [88-89]. In the majority of the cases, renal im‐
pairment is caused by the accumulation and precipitation of light chains, which forms casts
in the distal tubules, resulting in renal obstructions. In addition, myeloma light chains are
also directly toxic on proximal renal tubules, further adding to renal dysfunction [89-90].
Circulating monoclonal light chains are relatively freely filtered through the glomerulus,
reaching the proximal tubule, where they are catabolized. Free light chains are endocytosed
by proximal tubule cells, through a receptor-mediated process, by binding to the tandem
scavenger receptor system cubilin/megalin. Then, they are endocytosed through the cla‐
thrin-dependent endosomal/lysosomal pathways and degraded within lysosomes [91-94]. In
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MM, excess light chain production overcomes the capacity of the tubular cells to catabolize
the free light chains that appear in the tubular fluid of distal nephron segments. Therefore,
they form tubular casts with Tamm-Horsfall protein (uromodulin), a glycoprotein-synthe‐
sized by the cells in the medullary thick ascending limb of the loop of Henle with affinity for
monoclonal light chains. Light chains interact through their complementary determining re‐
gion with a specific binding site on the Tamm-Horsfall protein and form aggregates and
casts that subsequently lead to the tubular obstruction of the distal tubule and the thick as‐
cending loop of Henle [95-97]. Tubular obstruction increases intraluminal pressure, reduces
glomerular filtration rate and reduces interstitial blood flow, thus further compromising the
renal function [90]). The rates of cast formation increase when light chains increase, al‐
though there is considerable diversity among the nephrotoxicity of light chains. The variable
region of the light chain determines nephrotoxicity of the specific light chain by determining
the affinity with Tomm-Horsfall protein [98-99]. It has been indicated that Tamm-Horsfall
protein interacts with the hypervariable regions of the light chains. This region contains the
amino acids that give diversity, and allow for interactions with several proteins to promote
antigen binding by immunoglobulins [100-101]. In addition, the variable region of the light
chain determines the specific type of renal damage. Both lambda and kappa light chains are
nephrotoxic, but lambda light chains are more frequently involved in the formation of amy‐
loid than kappa [102]. The relationship between the type of light chain and the severity and
type of renal damage has not been investigated in animals yet.
In addition of casts formation, endocytosis of light chains by renal tubular cells induces pro-
inflammatory cytokine production (interleukin-6 and 8, tumor necrosis factor-α). These pro-
inflammatory cytokines promote infiltration by inflammatory cells that produce
metalloproteinases and increase transforming growth factor-b production, resulting in ma‐
trix protein deposition and fibrosis and further compromising the ability of the nephron to
restore function [103]. Light chains endocytosis might also cause tubular cell necrosis, lead‐
ing to more severe renal dysfunction [104], but the exact mechanism has not been described.
It has been hypothesized that the aggregation of light chains after endocytosis initiates a cas‐
cade leading to tubular cell death [105].
Other mechanisms that lead to renal insufficiency are tumor infiltration within the renal pa‐
renchyma, hypercalcemia, amyloidosis, decreased renal perfusion due to the HVS, dehydra‐
tion, ascending urinary tract infections and Bence-Jones proteinuria [4, 27]. In human
patients with MM, hypercalcemia is the second most common cause of renal failure. Hyper‐
calcemia is also probably an important predisposing factor to renal dysfunction in animals
with MM, since a tight relationship between renal failure and hypercalcemia has been de‐
scribed in many reports in veterinary medicine [106-108] Hypercalcemia interferes with re‐
nal function and impairs renal concentrating ability, causes vasoconstriction of renal
vasculature and enhances diuresis.
4.6. Heart disease
Heart disease may occur in patients with MM as a consequence of HVS related to myocar‐
dial hypoxia and increased cardiac workload. In addition, amyloid deposition in the myo‐
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cardium and anemia may exacerbate the severity of this condition [109]. Approximately 50%
of the cats with MM in one study had idiopathic heart murmur [4]. Recently, three cases of
cats evaluated for congestive heart failure with acute collapse, tachypnea, increased respira‐
tory effort, and pulmonary crackles, have been reported secondarily to HVS [54].
4.7. Other clinical signs
Neurological manifestations often complicate the course of MM, but direct involvement of
the central nervous system in rare in human patients, although there are some cases report‐
ed [110-113]. Similarly, neurological signs are uncommon manifestations of MM in animals.
However, it is well recognized that MM may lead to abnormalities of the central nervous
system either as a result of spinal cord compression by the neoplasm arising within a verte‐
bra or due to pathological fracture of a vertebra weakened by tumor infiltration [114-115]. It
could also be due to the HVS where sludging of blood within the vasculature results in cen‐
tral nervous system hypoxia [116]. Neurological signs associated with MM have been re‐
ported in horses [1,7], cats [31] and dogs [22,114]. Edwards et al. [1] described the cases of
three horses with rear leg paresis and/or ataxia. Spinal cord compression by an extradural
tumor mass was observed in one of the two horses in which the spinal canal was examined.
McConkey et al. [7] observed a horse with hind ataxia progressing to paralysis, with dys‐
phagia and ptyalism. These clinical signs were attributed to neoplastic involvement of the
trigeminal nerve. Similarly, Appel et al. [31] presented the case of a cat with hind limb loco‐
motor difficulties, signs of pain along the lumbar portion of the vertebral column, with al‐
tered motor function and moderate muscle atrophy. In this case, survey radiographs
revealed osteolytic lesions in lumbar vertebras [31].
In MM patients, peripheral neuropathy has for a long time been considered as mainly secon‐
dary to the tumor, following a direct compression (radicular or medullar), light chain depos‐
its (amyloidosis), cryoglobulinemia or an autoimmune mechanism [117-121]. A
paraneoplastic polyneuropathy is seen in association with IgM monoclonal gammopathy as‐
sociated with MM, Waldenstrom’s macroglobulinemia, primary amyloidosis and lympho‐
ma, as well as monoclonal gammopathy of undetermined significance. IgM-M proteins have
autoantibody activity and have been shown to bind to myelin associated glycoprotein re‐
sulting in a demyelinating peripheral neuropathy [121]. However, increased levels of cyto‐
kines are thought to cause the paraneoplastic neuropathy rather than an immune-mediated
mechanism [122-123]. Furthermore, with the use of new drugs, the iatrogenic neurotoxicity
has become the leading cause of peripheral neuropathy in people [124-126]. The commonest
nerve involvement appears to be in the form of sensory-motor axonal neuropathy followed
by sensory-motor demyelinating neuropathy [117].
In companion animals, paraneoplastic neuropathies have been reported sporadically in ma‐
lignant tumors, and include bronchogenic carcinoma, insulinoma, leiomyosarcoma, heman‐
giosarcoma, undifferentiated sarcoma, synovial sarcoma and adrenal adenocarcinoma
[114,127-129]. Viviers and Dobson [22] described the case of a 12-year-old female German
Shepherd dog that developed progressive hindlimb followed by forelimb ataxia with tetra‐
plejia. Neurological examination suggested lower motor dysfunction. MM was diagnosed
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by biochemical evaluation, radiography and bone marrow aspirate. An electromyogram re‐
vealed positive sharp waves and fibrillation potentials in the skeletal muscles of the limbs,
suggesting a polyneuropathy. Motor function started to improve four weeks after commenc‐
ing treatment. According to the authors, polyneuropathy in this dog appeared as a paraneo‐
plastic syndrome secondary to MM [22].
Cutaneous involvement in MM has also been described in animals, although it seems to
be  unusual.  Mayer  et  al.  [24]  described  the  case  of  an  8-year-old  Rottweiler  dog  with
more than 50 soft cutaneous and subcutaneous nodules, ranging from 0.5 to 2.5 cm in di‐
ameter, located primarily on the ventral aspects of the thorax and abdomen and the me‐
dial aspect of the thighs. Histopathological examination of excised subcutaneous modules
revealed  MM.  More  recently,  Fukumoto  et  al.  [16]  presented  the  case  of  a  7-year-old
male, mixed breed dog with more than 40 cutaneous nodules ranging from 0.5 to 1.0 cm
in  diameter,  mainly  on  the  abdomen  and  inguinal  region.  Cutaneous  involvement  has
not been described in horses with MM.
5. Diagnosis aids of multiple myeloma in veterinary medicine
5.1. Hematology
Anemia is  a  prominent feature of  MM, it  is  commonly associated with clinical  progres‐
sion in human patients and occurs in more than two thirds of all patients [130-132]. Sim‐
ilarly,  approximately  30%  of  dogs  and  75%  of  cats  with  MM  have  a  normocytic
normochromic  non-regenerative  anemia  [4,10,26-27,32-33]  and  anemia  is  also  invariably
present in horses with MM.
The  pathogenic  mechanisms  involved  in  the  anemia  are  chronic  inflammation,  tumor
hemorrhage and/or hemostatic abnormalities, myelophthisis,  increased red blood cell de‐
struction induced by the HVS,  plasma expansion secondary to the osmotic  effect  of  the
paraproteins and red cell  destruction by neoplastic  cells  [4,27,29].  In cats,  erythrophago‐
cytosis by neoplastic plasma cells [32], mast cells [133]), lymphocytes [134-135] and histo‐
cytes [136] has been observed.  In the same way,  there are several  reports  of  phagocytic
plasma cells  in  people  with  MM [137].  Although erythrophagocytic  plasma cells  in  hu‐
mans with MM are rare,  neoplastic plasma cells have been observed with phagocytosed
platelets and granulocytes [138]. The mechanism of hemophagocytosis in MM is unclear,
as plasma cells have not phagocytic function under normal circumstances. Results of the
direct antiglobulin test in humans are almost always negative, suggesting hemophagocy‐
tosis by neoplastic cells is not an autoimmune function [137]. It has been speculated that
phagocytic  plasma  cells  may  arise  as  an  expansion  of  a  rare  B-cell  clone  with  innate
phagocytic potential [137]. A single case of phagocytic plasma cells aberrantly expression
CD15 (normally found on neutrophils and monocytes and involved in phagocytosis) has
been reported in human beings [139].
Nevertheless, anemia of chronic disease appears to be of utmost importance in MM. Inter‐
leukin-1 and tumor necrosis factors are capable of suppressing erythropoiesis [130]. Anemia
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has broad implications in these patients. First, the low hemoglobin concentration and
packed cell volume have been associated with poor quality of life in people, and affect daily
activity. Second, anemia has an impact on the cardiovascular system. In fact, anemia has
been shown to induce or aggravate hypoxia and ischemic complications. Third, anemia has
been shown to be a poor prognostic factor in MM [140-142].
Data concerning white blood cell count (total and different subpopulations) are not consis‐
tent in animals with MM. It has been found lymphopenia [24,30,32], leukocytosis due to
neutrophilia [4,8], neutropenia with lymphocytosis [31], leukopenia [1,25,37], leukocytosis
with neutrophilia and lymphocytosis [31], neutropenia [16], neutrophenia with lymphope‐
nia [18], pancytopenia [10] and absence of white blood cell abnormalities [3,6,22].
Thrombocytopenia is reported in approximately one third of all canine patients of MM
[10,25,27]. It has also been described in cats [4,29] and horses [18,37]. However, there are
many other reports of MM in veterinary medicine with patients that show normal number
of platelets [3,6-8,16,22,24,31-32]. Thrombocytopenia that could promote bleeding disorders,
is proposed to result from infiltration of bone marrow by malignant plasma cells, consump‐
tion of platelets as part of thrombohemorrhagic syndrome, such as disseminated intravascu‐
lar coagulation, shortened platelet half-life or immune-mediated destruction, even though
the latter 2 mechanisms have yet to be verified in veterinary medicine [10,27,30,64,142-143].
5.2. Blood clinical biochemistry
5.2.1. Serum protein concentrations and serum protein electrophoresis
Hyperproteinemia, specifically hypoalbuminemia and hyperglobulinemia is very common
in MM, but not an invariable feature. Hypoalbuminemia has been described consistently in
MM in dogs [9,15-16,22-24], cats [3,9,29,32] and horses [1,3,18]. However, in the three animal
species, there are some reports that reported serum albumin concentrations within the refer‐
ence range in animals [6-8,31].
The mechanisms of the hypoalbuminemia are unknown, but in human beings is primarily
related to the extent of the proliferation of the MM and it is therefore of diagnostic and prog‐
nostic importance [144]. Several studies have suggested that low serum albumin concentra‐
tions correlate with increased serum concentrations of interleukin-6, a potent myeloma cell
growth factor, reflecting disease severity and cell proliferation [145-146]. Interleukin-6 is a
multifunctional, pro-inflammatory cytokine that stimulates B cell maturation and prolifera‐
tion and overproduction has been demonstrated in a variety of B-cell malignancies [147].
The neoplastic plasma cells are responsible for an overproduction of a homogeneous or
monoclonal immunoglobulin product, known as paraproteins o M-component. The para‐
proteins may be complete immunoglobulin, free light chains, light chains fragments or poly‐
mers, or partial immunoglobulins missing one or both chains [148]. The term monoclonal
gammopathy is commonly used to define hyperglobulinemia characterized by an electro‐
phoretic pattern with a sharply defined peak that is usually in the β- or γ- region and is nar‐
rower than the albumin peak [9,149]. When 2 narrow peaks with these features are
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recognized, the term biclonal gammopathy is often used. Monoclonal gammopathies are as‐
sociated with production of a single clone of immunoglobulin owing to clonal expansion of
neoplastic lymphoid cells, such as plasma cells in MM and B cells in lymphoma [9]. In con‐
trast, a polyclonal gammopathy is characterized by a broader peak or multiple peaks in the
γ- or β-γ regions. Polyclonal gammopathies are associated with chronic antigenic stimula‐
tion that occurs in chronic infections and other inflammatory conditions [148,150-152]. The
term oligoclonal gammopathy refers to an electrophoretic pattern that is similar to a mono‐
clonal one, but in which the globulin peak is slightly wider than the albumin peak [9,149].
Oligoclonal gammopathy may occasionally occur in animals with chronic inflammation or
infectious disease [9].
Although monoclonal gammopathy is the laboratory landmark of MM, other conditions oc‐
casionally can induce a monoclonal gammopathy in animals, such as chronic inflammation
(leishmaniosis, ehrlichiosis, chronic pioderma, feline infectious peritonitis)
[149-150,153-155], amyloidosis [156-157], B-cell lymphoma [149], Waldenströms macroglo‐
bulinemia [158-159] and monoclonal gammopathy of undefined significance (MGUS) [160].
The inclusion criterion for MGUS are M-protein and <10% bone marrow plasmacytosis, with
no evidence of lytic lesions, light chain proteinuria or other clinical, hematologic, and bio‐
chemical abnormalities [161-162]. MGUS occurs in 1-2% of people over the age of 50 and 3%
of people over the age of 70 [162]. A significant proportion (25%) of these will evolve within
20 years into MM, primary amyloidosis, macroglobulinemia or another lymphoproliferative
disease [162].
In dogs affected by MM, the incidence of IgA and IgG is comparable, whereas in cats and
horses IgG is most commonly involved [1,3-4,27]. In fact, of the 25 published feline MM with
immunoelectrophoresis results, 20 had IgG gammopathies, and 5 had IgA gammopathies
[2,13-14,85]. Similarly, there are some reports of IgA gammopathies in horses with MM [3,8].
Biclonal gammopathy, with two M-components has been reported in humans [163-165],
even though it was found to be very rare, occurring in about 1% of human beings with MM
[166]. Biclonal gammopathies have been described in lymphoproliferative disorders in dogs
and cats [2,9,19,23,167-168] including MM. The term biclonal is applied to the electrophoret‐
ic pattern and does not always correlate with true biclonal expansion because the biclonal
electrophoretic may arise from a single clone of B-cells, usually mature plasma cells that
produce one type of immunoglobulin with different dimerization patterns [9]. The biclonal
pattern may also occur from production of two different classes of immunoglobulins, usual‐
ly IgG and IgA, by two separate cell clones [23]. However, production of separate heavy
chain isotypes by a single clone of neoplastic cells, may result from isotype switching, which
occurs normally during B-cell maturation [9].
The prevalence of biclonal gammopathy in companion animals is unknown, but it could be
higher than reported. In many clinical veterinary laboratories, serum protein electrophoresis
is performed using cellulose acetate as the support medium. However, better separation of
protein fractions may be obtained using agar cell electrophoresis or capillary zone electro‐
phoresis. Facchini et al. [9] reported two cases (dog and cat) with gammopathies associated
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with MM that were interpreted as oligoclonal by standard cellulose acetate electrophoresis
but were determined to be biclonal con capillary zone electrophoresis.
MMs in veterinary patients lacking hyperglobulinemia have also been described [10]. The
authors propose that the lack of hyperglobulinemia resulted from either M-protein associat‐
ed secondary hypogammaglobulinemia or the IgA nature of the M protein. Secondary hypo‐
gammaglobulinemia with an immunosuppressive phenomenon associated with MM is
reported to occur in about 10% of human MM patients, and in a report, is most commonly
seen in secretory immunoglobulin A- MM [169-172]. The mechanism underlying MM-asso‐
ciated hypogammaglobulinemia is unclear, but recent work suggest that appropriate B-cell
maturation and immunoglobulin production are impaired by defects in CD4+, CD45R+, na‐
ïve T cells and increases in CD8+, CD11b1+ memory T cells [173-174]. The depression of nor‐
mal immunoglobulin production associated with exuberant M protein production has been
described anecdotally, but not specifically described in dogs with MM [64]. Seelig et al. [10]
supported their hypothesis in the immunoglobulin quantification data, which indicate mas‐
sive production of the immunoglobulin A M-protein and mild to moderate decreases in im‐
munoglobulins G and M in a dog.
Cryoglobulinemia has also been described in human patients with MM [175-176]. Cryoglo‐
bulins are proteins, usually immunoglobulins that precipitate as serum is cooled to tempera‐
ture less than body temperature and dissolve upon rewarming. They are most commonly
evident as a white gelatinous material but may sometimes appear crystalline or flocculent
[177] Cryoglobulinemia is rare in animals and are limited descriptions in dogs with MM
[114,178], in a dog with Waldenström’s macroglobulenia [179], in a cat [28], in a horse with
lymphoma [180], and in several horses with glomerulonephritis [181-182]. In human pa‐
tients, cryoglobulins are classified into 3 groups on the basis of their immunoglobulin com‐
position. In type-1 cryoglobulinemia a single monoclonal immunoglobulin, usually IgM is
present. This is most commonly associated with lymphoproliferative disorders such as MM,
Waldenström’s macroglobulinemia, lymphoma, and lymphocytic leukemia, but occasionally
can develop in conjunction with immune-mediated diseases [177]. In type II cryoglobuline‐
mia, a monoclonal immunoglobulin, usually IgM complexes with polyclonal IgG, whereas
in type III cryoglobulinemia, polyclonal immunoglobulins, usually immunoglobulin M com‐
plex with polyclonal immunoglobulin G. Type II and III cryoglobulinemia and may develop
secondary to infection, immune-mediated diseases or very rarely, lymphoproliferative dis‐
ease. In some instances, an underlying disease is not found and the cryoglobulinemia is de‐
scribed as essential. Using this classification system, type-I and mixed cryoglobulinemia in
dogs, horses and cats have been described. Two dogs with MM had type-I immunoglobulin
A cryoglobulinemia [114,178] and the dog with Waldenström’s macroglobulinemia had
type-I immunoglobulin M cryoglobulinemia [179]. Another dog had an essential mixed im‐
munoglobulin G-M cryoglobulinemia and cryofibrinogenemia [183], and although a thor‐
ough investigation for the underlying disease was not performed, the diagnosis was
supported by resolution and lack of recurrence of clinical signs when the dog was main‐
tained in a warm environment [183]. A cat had type I immunoglobulin G cryoglobulinemia
in association with MM [28].
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The typical clinical signs of cryoglobulinemia are purpura, cold intolerance, acrocyanosis
and ulceration, necrosis and gangrene of the skin of the distal extremities [184]. However of
the cases of cryoglobulinemia reported in the veterinary literature, only 1 dog [183] and 2
horses [180,182] had typical lesions. Necrosis of the pinnae occurred in the dog [183] and in
1 of the horses [180] and distal limb swelling and ulceration in other horse [182]. Similarly,
<50% of human patients with cryoglobulinemia have typical clinical signs even in cold con‐
ditions [184]. The lesions develop as a result of precipitation of cryoglobulin in small-diame‐
ter blood vessels, which causes vascular occlusion and tissue ischemia. Subsequently,
inflammation may develop at the site of precipitation secondary to complement fixation by
immunoglobulin G [185]. Despite extensive investigation, the physical and chemical charac‐
teristics accounting for the temperature-dependent solubility of cryoglobulins have not been
determined. Proposed mechanisms include altered amino acid or carbohydrate content of
the cryoglobin, leading to abnormal interactions between water and the protein [185].
5.2.2. Serum urea and creatinine concentrations
Azotemia is present in half of MM human patients when first evaluated [78-79]. Similarly,
many animals with MM show azotemia when presented [1,4,10,24,27,29], whereas there are
other cases with serum urea and creatinine concentrations within the reference limits
[3,6,22]. Probably these differences depend on the existence of renal kidney and on the de‐
gree of hydration.
5.2.3. Serum total and ionized calcium concentrations
Hypercalcemia has been reported in approximately 15-20% of dogs and 20-25% of cats af‐
fected by MM [4,29,65]. Similarly, hypercalcemia seems to be common in horses with MM
[1,3,8], although there is a report of hypocalcemia in one horse with MM [18].
Hypercalcemia is a complication of uncontrolled osteolysis, influenced in part by osteoclast
activation factor and in human patients has been associated with extensive osteolytic disease
[86]. However, MM-associated hypercalcemia is not reported as frequently as bone lysis
[4,27,35,64], perhaps because disease progression is usually slow, allowing for appropriate
metabolic controls. Other mechanisms of hypercalcemia are the release of an osteoclast acti‐
vating factor by either the bone marrow microenvironment or by neoplastic cells located in
bone [186-190]. In humans, interleukin-1, interleukin-6, tumor necrosis factor and the recep‐
tor activator of the nuclear factor kappa B ligand (RANKL) all modulated osteoclast activity
and may contribute to hypercalcemia [191]. Paratyroid hormone related peptide (PTH-rP)
also may contribute to the pathogenesis of MM-related hypercalcemia. It seems that essen‐
tially every cell of the body makes PTHrP under normal conditions [192-193]. It has a broad
range of physiological functions, including stimulation of bone resorption, vasorelaxation,
and cell proliferation, regulation of placental calcium transport, organogenesis, parturition,
lactation, and vascular smooth muscle proliferation and development of the skeletal system
[193]. Despite its wide distribution of the body, PTHrP is normally present in minute
amounts in the circulation [193-194] and high serum PTHrP concentrations have been found
in conjunction only with pathologic conditions, principally malignancy [194-195]. PTHrP
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may be synthesized by normal cells activated by the presence of a malignancy or by neo‐
plastic cells. There is a report of a horse with MM and high concentrations of PTHrP [8]).
High levels of PTHrP have been also described in other neoplasms, such as thymoma [196],
nasal carcinoma [197], squamous cell carcinomas [198], angiomyxoma [199], mammary car‐
cinoma [200], lymphoma [201-203] adenocarcinoma of the apocrine gland of the anal sac
[203] and malignant melanoma [204].
The measurement of ionized calcium is recommended to confirm hypercalcemia in these pa‐
tients, because binding of calcium by the M protein will increase total calcium concentration,
while ionized calcium will remain within normal limits [205]. Therefore, increased ionized
calcium concentrations supports true hypercalcemia. There is a recent report that present a
case of MM in a dog with increased total serum calcium concentration, but with serum ion‐
ized calcium concentrations within normal limits [25]. The authors suggested that the major‐
ity of the calcium was protein-bound to serum M proteins. In fact, serum calcium exists in
two major fractions, free and protein bound. A small portion of calcium is bound to other
small anions such as citrate, lactate, and phosphate. Because ionized calcium is the physio‐
logically active species of blood calcium, it is ordinarily maintained within very narrow lim‐
its by rigidly controlled mechanisms [205-206]. Approximately half of normal total serum
calcium is bound to negatively charged sites on albumin. Human MM has been reported to
bind calcium on the Fab portion of the globulin molecules [148].
MM is frequently complicated by an increase in the concentration of ionized calcium, which
if persistent leads to secondary nephrogenic diabetes insipidus and loss of the renal medul‐
lary concentration gradient causing polyuria and polydipsia [25].
5.2.4. Alterations in the coagulation profile
Approximately 50% of dogs affected by MM have abnormal prothrombin and partial throm‐
boplastin times [149,207] and these abnormalities have also been found in horses [6,18,37,86]
and cats [4,29]. However, other animals with MM had normal bleeding times [3,22].
Coagulation defects can result from paraproteins interference with clotting factors, protein
coating of platelets leading to thrombocytopenia and binding of the Fab fragment of the M-
protein to fibrin, preventing aggregation [116,208].
5.2.5. Alterations in serum sodium concentrations
Three horses with MM were hyponatremia [1]. The decreased concentrations could have re‐
sulted from displacement of the aqueous phase of plasma by the hyperglobulinemia. How‐
ever, true hyponatremia in human beings with MM has been described. Suggested
mechanism include displacement of sodium by cationic paraproteins, decreased plasma wa‐
ter secondary to unusual hydration characteristics of paraproteins, and syndrome of inap‐
propriate antidiuretic hormone release [209-210]. Alterations in serum sodium
concentrations do not appear to be common in small animals.
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5.2.6. Alterations in serum cholesterol concentrations
Hypocholesterolemia has been noted in approximately 69% of affected cats in one study [4].
Similarly, hypocholesterolemia was found in a horse with MM [1]. The incidence in cats is
higher than in human patients [211-212]. Serum cholesterol concentrations are thought to be
correlated inversely with globulin concentrations [35,211]. It has been postulated that the
hypocholesterolemia is the result of a down-regulation of cholesterol production by the liver
to maintain oncotic pressure in the face of hyperglobulinemia [78]). The main causes of hy‐
pocholesterolemia in veterinary medicine include protein-losing enteropathies, severe mal‐
nutrition, hepatic insufficiency or hyperthyroidism [213-215].
5.3. Urinalysis
Proteinuria, detected by routine urinalysis is present in 90%of human patients with MM
[216-221]. In the same way, proteinuria using dipsticks has been found in horses [1,3,6],
dogs [10,22] and cats [4,28,30,32] with MM. However, dipsticks detect primarily albuminu‐
ria and therefore, the sulfosalicylic acid test (SSA) provides greater sensitivity for globulin
detection but specificity is low due to the concomitant detection of albumin, globulin, Bence
Jones proteins, proteases and polypeptides. False positive SSA results may occur with peni‐
cillin and its derivatives, tolbutamide or sulfisoxazole metabolites, or certain contrast media
in the urine [222]. In people, false positive results for Bence Jones proteins detected by
means of heat precipitation can occur due to excessive amount of polyclonal light chain pro‐
teins in patients affected by a variety of conditions, including connective tissue diseases,
non-plasmacytic tumors and chronic renal failure [4,216,222]. Therefore, urine protein elec‐
trophoresis remains the preferred diagnostic modality to detect monoclonal proteinuria,
even is not always used in veterinary medicine.
Bence Jones proteinuria has been estimated to occur in approximately 25-40% of dogs an ap‐
proximately 65% of cats with MM [4,27,29]. Similarly, it has been determined in horses with
MM [1,3].
5.4. Diagnostic ancillary aids
Survey radiographies and echographies are required for screening of skeletal lesions and
identification of abdominal organ neoplasia respectively. Furthermore, a funduscopic ex‐
amination should be carried out in patients suspicious of MM, mainly in small animals, in
order to rule out ocular lesions associated with the HVS, such as retinal hemorrhages, retinal
detachment, venous tortuosity, dilation, sacculation, and blindness.
As explained before, skeletal lesions vary from areas of osteopenias observed in early stages
of the disease to lytic lesions typical of later stages. Biopsy and histopathology of a lytic le‐
sion may sometimes be necessary for a definitive diagnosis. Survey radiographies are com‐
monly performed now in small animals with MM, because increased clinician awareness of
the lesions, better quality radiographs and increased knowledge about the disease. In horses
with MM, survey radiographies are less used, probably because of the higher incidence of
skeletal lesions of other origin (sport horses). Lung radiography is recommended in equine
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patients with MM in order to rule out pneumonia, one common finding in these cases [3,18].
In addition, hepatomegaly (58%), splenomegaly (25%), cardiomegaly (67%) and renomegaly
(9%) have been detected in cats with MM [4,29].
The most common ultrasonographic abnormalities involved the spleen and the liver and to
a lesser extent the kidneys [4]. In cats, the most consistent finding in MM is splenic enlarge‐
ment and diffuse or nodular hypoechogenicity. The most consistent hepatic abnormality is
diffuse hyperechogenicity and enlargement [4]. Bone marrow cytology should be done to
confirm the diagnosis. A detailed description of the histopathological characteristics in bone
marrow and in other organs after necropsy, consistent with MM is out of the scope of the
present review.
5.5. Diagnostic criteria
Current published recommendations for determining a diagnosis in veterinary medicine in‐
dicate that the animal should have at least 2 of the following 4 criteria: 1) Bone marrow plas‐
macytosis with >20% plasma cells; 2) Monoclonal gammopathy based on serum protein
electrophoresis; 3) Osteolysis and 4) Light chain (Bence-Jones) proteinuria (2). These criteria
are unweighted for animal patients. In human patients, criteria are weighted as ‘major’ and
‘minor’ and accommodate lower plasma cell percentages (17). In people, confirmation of
MM requires first that the patient be symptomatic (i.e. have bone pain) or have anemia, hy‐
percalcemia, azotemia, hypoalbuminemia, or bone demineralization. The diagnostic criteria
of MM are then applied. Major criteria include: 1) plasmacytoma(s) with biopsy; 2) marrow
plasmatocytosis >30%; 3) M-protein with >3.5 g/dl immunoglobulin G or 2.0 g/dl immuno‐
globulin A and 4) κ or λ chain excretion on 24-h urine protein electrophoresis. The 4 minor
criteria include: a) marrow plasmacytosis with 10-30% plasma cells; b) M-protein at values
less than indicated above; c) lytic bone lesions and d) >50% normal serum immunoglobulin
concentration. If the diagnosis includes major criteria, then any 2 of the 4 will suffice, or ma‐
jor criterion 1 plus minor criterion b, c, or d; or major criterion 3 plus minor criterion a or c.
If the diagnosis is based on only minor criteria, then it must include the first and second cri‐
teria (a and b), plus 1 of the remaining 2 criteria (c or d). This system has been recently incor‐
porated for the diagnosis in animals [4,10,24,31-32]. However, some modifications have been
introduced. Plasma cell atypia has been included as a criterion when marrow plasmacytosis
was between 10 and 20%. In humans, nuclear-cytoplasmic maturation asynchrony, nuclear
immaturity, and pleomorphism are considered reliable markers for distinguishing neoplas‐
tic cells from reactive plasma cells [223]. In addition, reactive plasma cells usually do not ex‐
ceed 5% of all nucleated cells in marrow and are well differentiated [223-224].
6. Treatment options in veterinary patients with mm
Treatment of MM with oral melphalan and glucocorticoids (prednisone or prednisolone) is
the standard of therapy due to its dual ability to reduce the bulk of the tumor and the symp‐
toms of the decrease [16,22-25,31-33,225]. Although complete eradication is only rarely ach‐
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ieved, chemotherapy is often effective in decreasing tumor burden, reducing serum
immunoglobulin levels, promoting bone remodeling and providing symptomatic relief. Fur‐
ther, this treatment leads to improved quality and possible duration of life [27,225] and is
also used in human patients with MM [226-230].
Melphalan is an alkylating agent whose oral absorption is unpredictable, requiring adminis‐
tration to be made preferable on the empty stomach. In dogs, melphalan is initially adminis‐
tered at 0.1 mg/kg PO once a day for 10 days and then 0.05 mg/kg PO every other day. In
cats, they are administered at 0.5-2.0 mg/kg PO once a day. Melphalan is combined with
glucocorticoids, prednisone [22,24-25,42] or less common, prednisolone [25,30-31]. Glucocor‐
ticoids have been shown to induce apoptosis in vitro via inhibition of Iκβ activation and de‐
creased nuclear factor κB activity [231-232]. Prednisone in dogs with MM is generally
administered at 1.0 mg/kg for the first 10 days of therapy and then, decreased to 0.5 mg/kg
every other day [22,24-25,32,225]. This combination treatment is continued indefinitely, until
relapse or myelosuppression.
Other alkylating drugs including cyclophosphamide, chlorambucil and 1(2-chloroethyl)-3-
cyclohexyl-1-nitrosourea (CCNU) have also been used to treat MM in small animals [10,233].
The addition of cyclophosphamide to a prednisone- melphalan regimen may be beneficial to
patients with severe clinical signs and/or hypercalcemia. Due to its platelet-sparing effect,
cyclophosphamide may be used in place of melphalan in thrombocytopenic patients, al‐
though this drug can have severe suppressive effects on other bone marrow lineages
[234-237]. Chorambucil, administered at 0.2 mg/kg PO once daily has been used successful
for the treatment of immunoglobulin M macroglobulinemia in dogs [159].
Combination chemotherapy protocols incorporating vincristine, carmustine, melphalan, cy‐
clophosphamide and prednisone or vincristine, melphalan, cyclophosphamide and predni‐
sone have been used in human beings, but outcomes are essentially comparable to those of
patients with melphalan and prednisone alone [238-241]. The administration of high dose
dexamethasone in conjunction with vincristine and doxorubicin was investigated in humans
with refractory MM and resulted in a response greater than 50%. Rapid tumor response, al‐
leviation of bone pain, resolution of hypercalcemia and absence of damage to bone marrow
stem cells were remarkable advantages to this treatment combination [239]. Anecdotally, in
dogs, responses of a few months duration have been achieved with a combination of doxor‐
ubicin, vincristine and prednisone in lymphoma [242-243] and in MM [10].
The efficacy of inteferon for the treatment of MM is controversial [244-245]. While a re‐
sponse rate of approximately 20% was reported in humans with relapsed MM, the addition
of interferon to standard chemotherapy approaches failed to provide a significant benefit to
the overall survival time in a meta-analysis of 2286 patients [244]. However, there is other
report that stated that even though most interferon benefits to MM patients are relatively
small when viewed in the light of survival expectancies, they seem clinically relevant. Since
median overall survival of conventionally treated MM patients ranges between 30 and 50
months, 3-7 months gains of life amount to a increase of 10-25% [244].
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High-dose chemotherapy in association with autologous transplantations using bone mar‐
row or blood-derived stem cells is now widely accepted for the treatment of hematological
malignancies including MM. This approach yielded to complete remissions in refractory hu‐
man patients, but mortality rate due to bone marrow suppression was high. Contamination
of most bone marrow and blood stem cell samples with neoplastic cells within the auto‐
graph resulted in recurrence of disease, emphasizing the need of optimize purging techni‐
ques [246-250]. Autologous bone marrow transplant has also been added to chemotherapy
in the treatment of some malignancies in companion animals, such as lymphoma and acute
myeloid leukemia [251-253].
In human patients with MM, biphosphonates such as pamidronate, have been used to pre‐
vent or to delay the onset of bone lesions and associated bone pain [254-257]. Bisphospho‐
nates have been administered in dogs with appendicular osteosarcoma [258-259] and with
malignant histiocytosis [260], but they have not been used in veterinary patients with MM.
Treatment of patients affected by indolent MM with the anti-angiogenic agent thalidomide
resulted in a 66% response rate and the drug appeared to have potential to delay the onset
of clinical signs associated with the disease [261-262]. The efficacy of thalidomide for the
treatment of refractory relapsed MM has also been confirmed [263-265]. Studies evaluating
the possible efficacy of thalidomide for the treatment of MM in companion animals are lack‐
ing. Bortezomib, a proteasome inhibitor, induces apoptosis of MM cells and inhibits their
binding to bone marrow stromal cells, which otherwise would trigger the transcription of
interleukin-6 via an NFκB-dependent pathway. In different studies a 25% response rate was
achieved in human beings with MM and an overall survival time of 16 months. Further‐
more, addition of dexamethasone to the treatment regimen improved responses in 19% of
treated patients [227-228,264,266].
Additional, some patients experience severe clinical signs secondary to hypercalcemia, renal
dysfunction, HVS or pathologic fractures will require palliative therapy specifically directed
to the clinical complications of the disease.
7. Prognosis of companion animals with multiple myeloma
Unfortunately, the prognosis of companion animals with MM is poor. The mean survival
time in dogs treated with MM and treated with melphalan, cyclophosphamide and predni‐
sone is 540 days after diagnosis [27]. In dogs, negative prognostic factors include extensive
bone lesions, hypercalcemia and light chain proteinuria. Renal insufficiency and poor initial
response to therapy also may be associated with decreased survival times [27]. In a study of
9 cats with MM, it was found that hypercalcemia, pathologic fractures, anemia, Bence-Jones
proteinuria, azotemia, persistent elevations in serum protein concentrations at 8 weeks after
treatment and little or no clinical improvement were poor prognostic indicators and reflect‐
ed a more aggressive form of the disease [29]. Survival time for such cats did not exceed 14
days, with a median of 5 days. In contrast, normocalcemia, lack of azotemia, absence of
pathologic fractures, no anemia, absence of Bence-Jones proteinuria and a normal serum
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protein 8 weeks after commencement of treatment reflected a less aggressive form with a
median survival of 387 days (range between 120 and 720 days) [29].
In a study, a possible relationship between prognosis and immunoglobulin isotype was sug‐
gested in cats with MM [2], even though there are few detailed cases. Although immunoglo‐
bulin A appears to be less commonly produced than immunoglobulin G in cats, as described
before, the published cases with immunoglobulin A paraproteins had visceral involvement
and decreased survival time (ranging from a few days to 6 months) [12,65,267-268]. Either
immunoglobulin has been associated with clinical signs of HVS, including cardiac insuffi‐
ciency, retinal hemorrhages and neurological signs [85,268]. This phenomenon relates to the
size of the paraproteins and the degree of hyperglobulinemia. Since immunoglobulin A may
assume a dimeric or multimeric form, it may be more commonly associated with hypervis‐
cosity than immunoglobulin G. HVS can contribute to decreased survival time in animals
with MM [13,23,54,85].
The lifespan of horses diagnosed of MM usually does not exceed two years [1,3,6,8]. There is
not any published case of equine MM that attempted chemotherapy and most horses are eu‐
thanized owing to the advance stage of the disease.
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